Skip to main content

Table 2 Antimicrobial use stratified by receipt of immunosuppression

From: The impact of immunosuppressive therapy on secondary infections and antimicrobial use in COVID-19 inpatients: a retrospective cohort study

Characteristic

Overall, N = 7151

High-dose immunosuppression

p-value

No, N = 6481

Yes, N = 671

Received any antimicrobial

606 (85%)

542 (84%)

64 (96%)

0.012

Number of antimicrobial courses

2 (1, 3)

2 (1, 3)

3 (2, 5)

 < 0.0013

Antimicrobial Days of Treatment

8 (4, 14)

8 (3, 13)

12 (8, 18)

 < 0.0013

Received an Access antibiotic

504 (70%)

446 (69%)

58 (87%)

0.0022

Received a Watch antibiotic

429 (60%)

385 (59%)

44 (66%)

0.32

Received a Reserve antibiotic

45 (6%)

36 (6%)

9 (13%)

0.34

Received an antifungal

32 (4%)

24 (4%)

8 (12%)

0.0074

  1. 1Median (IQR) for continuous variables; n (column % of non-missing data) for categorical variables
  2. 2Pearson’s Chi-squared test
  3. 3Wilcoxon rank sum test
  4. 4Fisher’s exact test